Press Release Source: Kindred Biosciences, Inc.
Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that Denise Bevers, co-founder and chief operating officer of KindredBio, has been elected to its Board of Directors and promoted to President.
Since co-founding KindredBio in 2012, Bevers has assumed increasing levels of responsibility and has been instrumental in growing KindredBio into one of the world’s leading veterinary biopharmaceutical companies, the company stated. In her expanded role as president, Bevers will be responsible for all operational functions. She will retain her title as COO and continue to oversee the commercial organization, including the launch of KindredBio’s first product, Mirataz (mirtazapine transdermal ointment).
“Denise is a remarkably talented leader and it is a pleasure to announce her well-deserved promotion and election to our Board,” said Richard Chin, chief executive officer of KindredBio. “As KindredBio’s co-founder, she has been critical in our successes, including our recent transition to a commercial-stage company, and in our mission to transform veterinary medicine.”
Bevers is an experienced pharmaceutical executive with a distinguished career in clinical operations, medical affairs, and scientific communications. With over 20 years of pharmaceutical and research experience, she has successfully managed dozens of product launches and development programs from Phase I through Phase IV. Bevers previously held leadership positions at Elan Pharmaceuticals, Scripps Clinic and Research Foundation, Quintiles, and SkyePharma. Prior to co-founding KindredBio, she was president and founding partner of SD Scientific, a full-service medical affairs and communications company.